{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:18:34Z","timestamp":1791173914483,"version":"4.1.0"},"reference-count":21,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,7,18]],"date-time":"2006-07-18T00:00:00Z","timestamp":1153180800000},"content-version":"vor","delay-in-days":4008,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[1995,7,28]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The CD 19<jats:sup>+<\/jats:sup> CD38<jats:sup>+<\/jats:sup> human Burkitt's lymphoma cell line Ramos grows aggressively when injected intravenously (i.v.) into severe combined immunodeficient (SCID) mice, killing 100% of animals within a 33\u201342 day period with widely disseminated disease. Treatment commencing 7 days after i.v. injection of Ramos cells, with 3 doses of an anti\u2010CD 19 immunotoxin (IT; BU12\u2010SAPORIN) or an anti\u2010CD38 IT (OKTIO\u2010SAPORIN) led to a significant prolongation of survival compared with shamtreated controls; the anti\u2010CD38 IT gave the greatest prolongation of survival, but all treated animals eventually succumbed to disease. When both ITs were used in combination at equivalent dose levels, the therapeutic outcome was significantly improved over that obtained for single IT therapy, with 20% of animals surviving disease\u2010free to 300 days. When anti\u2010CD38 IT was given in combination with anti\u2010CD 19 antibody there was no therapeutic improvement over anti\u2010CD38 IT used alone. However, when anti\u2010CD 19 IT was given in combination with CD38 antibody, a significant prolongation of survival ensued over that obtained with anti\u2010CD 19 IT alone, though this was not as significantly pronounced as that obtained when both ITs were used in combination and was only as good as the survival obtained with OKT10 antibody used alone. CD 19 and CD38 are expressed on the surface of the vast majority of B\u2010cell lymphoma and common acute lymphoblastic leukaemia cells, and our findings provide a sound rationale for a combination immunotoxin trial in these diseases directed against both these target molecules. \u00a9 1995 Wiley\u2010Liss Inc.<\/jats:p>","DOI":"10.1002\/ijc.2910620318","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T00:47:36Z","timestamp":1171932456000},"page":"337-344","source":"Crossref","is-referenced-by-count":26,"title":["Therapy of human B\u2010cell lymphoma bearing scid mice is more effective with anti\u2010CD19\u2010and anti\u2010CD38\u2010saporin immunotoxins used in combination than with either immunotoxin used alone"],"prefix":"10.1002","volume":"62","author":[{"given":"David J.","family":"Flavell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Boehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armorel","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Ramsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sopsamorn U.","family":"Flavell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,7,18]]},"reference":[{"key":"e_1_2_1_1_1","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood.V82.9.2624.2624","article-title":"13 others. A phase I study of an anti\u2010CD22\u2010deglycosylated ricin A chain immunotoxin in the treatment of B\u2010cell lymphomas resistant to conventional therapy","volume":"82","author":"Amlot P. L.","year":"1993","journal-title":"Blood"},{"key":"e_1_2_1_2_1","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.4049\/jimmunol.135.5.2911","article-title":"Evidence that lymphokine\u2010activated killer cells and natural killer cells are distinct based on an analysis of congenitally immunodeficient mice","volume":"135","author":"Andriole G. L.","year":"1985","journal-title":"J. Immunol."},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0008-8749(89)90385-7"},{"key":"e_1_2_1_4_1","first-page":"3056","article-title":"C. Efficacy of an anti\u2010CD7\u2010ricin A chain immunoconjugate in a novel murine model of human T\u2010cell leukaemia","volume":"52","author":"Fishwild D. M.","year":"1992","journal-title":"Cancer Res."},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1991.291"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1992.112"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910580317"},{"key":"e_1_2_1_8_1","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood.V83.5.1329.1329","article-title":"Anti\u2010CD19 inhibits the growth of human B\u2010cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest","volume":"83","author":"Ghetie A.\u2010M.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_1_9_1","first-page":"2351","article-title":"The antitumour activity of an anti\u2010CD22 immunotoxin in SCID mice with disseminated daudi lymphoma in enhanced by either an anti\u2010CD19 antibody or an anti\u2010CD19 immunotoxin","volume":"80","author":"Ghetie M.\u2010A.","year":"1992","journal-title":"Blood"},{"key":"e_1_2_1_10_1","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1182\/blood.V84.3.702.702","article-title":"Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail","volume":"84","author":"Ghetie M. A.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_1_11_1","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1182\/blood.V79.3.576.576","article-title":"Serotherapy of B\u2010cell neoplasms with anti\u2010B4\u2010blocked ricin. A phase I trial of daily bolus infusion","volume":"79","author":"Grossbard M. L.","year":"1992","journal-title":"Blood"},{"key":"e_1_2_1_12_1","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1182\/blood.V81.9.2263.2263","article-title":"Adjuvant immunotoxin therapy with anti\u2010B4\u2010blocked ricin after autologous bone marrow transplantation for patients with B\u2010cell non\u2010Hodgkin's lymphoma","volume":"81","author":"Grossbard M. L.","year":"1993","journal-title":"Blood"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000149930"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/227680a0"},{"key":"e_1_2_1_15_1","doi-asserted-by":"crossref","first-page":"12035","DOI":"10.1016\/S0021-9258(17)38981-0","article-title":"Purified immunotoxins that are reactive with human lymphoid cells. MAbs conjugated to the RIP's gelonin and PAP","volume":"260","author":"Lambert J. M.","year":"1983","journal-title":"J. biol. Chem."},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj2160617"},{"key":"e_1_2_1_17_1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1182\/blood.V66.3.627.627","article-title":"Use of multiple T\u2010cell\u2010directed intact ricin immunotoxins for autologous bone marrow transplantation","volume":"66","author":"Strong R. C.","year":"1985","journal-title":"Blood"},{"key":"e_1_2_1_18_1","first-page":"151","article-title":"An immunotoxin composed of monoclonal anti\u2010Thy 1.1 antibody and a ribosome\u2010inactivating protein from Saponaria officinalis: potent antitumor effects in vitro andin vivo","volume":"75","author":"Thorpe P. E.","year":"1985","journal-title":"J. nat. Cancer Inst."},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb03329.x"},{"key":"e_1_2_1_20_1","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1182\/blood.V79.9.2201.2201","article-title":"In vivo efficacy of B43 (anti\u2010CD19)\u2010pokeweed antiviral protein immunotoxin against human pre\u2010B\u2010cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency","volume":"79","author":"Uckun F. M.","year":"1992","journal-title":"Blood"},{"key":"e_1_2_1_21_1","first-page":"4052","article-title":"Phase I immunotoxin trial in patients with B\u2010cell lymphoma","volume":"51","author":"Vitetta E. S.","year":"1991","journal-title":"Cancer Res."}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.2910620318","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.2910620318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T05:44:35Z","timestamp":1698299075000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.2910620318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,7,28]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1995,7,28]]}},"alternative-id":["10.1002\/ijc.2910620318"],"URL":"https:\/\/doi.org\/10.1002\/ijc.2910620318","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,7,28]]}}}